Despite evidence of increased Aβ42-α7nAChR complex levels in lymphocytes from AD subjects [7], it remains ambiguous whether an increased Aβ42-α7nAChR complex level in lymphocytes may be a reliable AD biomarker. This evidence concerns the gene CHRNA7 and Alzheimer disease.